Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

Core Insights - Arcus Biosciences, Inc. announced the first overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study focusing on patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma [1] Company Summary - Arcus Biosciences is a clinical-stage global biopharmaceutical company dedicated to developing differentiated molecules and combination therapies for cancer patients [1] - The ongoing Phase 2 EDGE-Gastric study is a multi-arm global trial evaluating treatment options for specific types of advanced gastric cancers [1]